Literature DB >> 29966628

Pulmonary Hypertension and Heart Failure: A Dangerous Liaison.

Marco Guazzi1.   

Abstract

Pulmonary hypertension (PH) is a common hemodynamic evolution of heart failure (HF) with preserved or reduced ejection fraction, responsible for congestion, symptoms worsening, exercise limitation, and negative outcome. In HF of any origin, PH develops in response to a passive backward pressure transmission as result of increased left atrial pressure. Sustained pressure injury and chronic venous congestion can trigger pulmonary vasoconstriction and vascular remodeling, leading to irreversible pulmonary vascular disease, right ventricular hypertrophy, and failure. In this article, the key determinants of this "dangerous liaison" are analyzed with some digressions on related "leitmotiv" at the horizon.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Heart failure; Left atrial pressure; Mean pulmonary artery pressure; Pulmonary hypertension; Pulmonary vascular resistance; Right heart dysfunction

Mesh:

Year:  2018        PMID: 29966628     DOI: 10.1016/j.hfc.2018.02.006

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  4 in total

Review 1.  A right ventricular state of mind in the progression of heart failure with reduced ejection fraction: implications for left ventricular assist device therapy.

Authors:  Ersilia M DeFilippis; Marco Guazzi; Paolo C Colombo; Melana Yuzefpolskaya
Journal:  Heart Fail Rev       Date:  2021-11       Impact factor: 4.214

2.  Outcome of patients with heart failure after transcatheter aortic valve implantation.

Authors:  Ulrich Fischer-Rasokat; Matthias Renker; Christoph Liebetrau; Maren Weferling; Andreas Rolf; Mirko Doss; Helge Möllmann; Thomas Walther; Christian W Hamm; Won-Keun Kim
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

3.  Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status.

Authors:  Maxime Tremblay-Gravel; Annik Fortier; Cantin Baron; Chloé David; Pamela Mehanna; Anique Ducharme; Julie Hussin; Qinghua Hu; Jean-Claude Tardif; Christine Des Rosiers; Jocelyn Dupuis; Matthieu Ruiz
Journal:  Metabolites       Date:  2021-03-26

4.  Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.

Authors:  Trond J Cooper; John G F Cleland; Marco Guazzi; Pierpaolo Pellicori; Tuvia Ben Gal; Offer Amir; Abdallah Al-Mohammad; Andrew L Clark; Alex McConnachie; Kjetil Steine; Kenneth Dickstein
Journal:  Eur J Heart Fail       Date:  2022-06-06       Impact factor: 17.349

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.